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Outer membrane protein A (OmpA) is a conserved
major component of the outer membrane of Entero-
bacteriaceae. Here, we report that OmpA from Kleb-
siella pneumoniae (KpOmpA) activates macrophages
and dendritic cells (DCs) in a TLR2-dependent way.
However, TLR2 does not account for binding of
KpOmpA to innate immune cells. KpOmpA binds the
scavenger receptors (SRs) LOX-1 and SREC-I, but not
other members of the same family. LOX-1 colocalizes
and cooperates with TLR2 in triggering cellular re-
sponses. The TLR2-activated functional program in-
cludes production of the long pentraxin PTX3, a solu-
ble pattern recognition receptor involved in resistance
against diverse pathogens. PTX3, in turn, binds
KpOmpA but does not affect recognition of this mi-
crobial moiety by cellular receptors. KpOmpA-elicited*Correspondence: mantovani@marionegri.it
8 These authors contributed equally to this work.in vivo inflammation is abrogated in TLR2−/− mice and
significantly reduced in PTX3−/− mice. Thus, SR-medi-
ated KpOmpA recognition and TLR2-dependent cellu-
lar activation set in motion a nonredundant PTX3-
mediated humoral amplification loop of innate immunity.
Introduction
Innate immunity is the first line of defense against path-
ogens and plays a key role in the activation and orienta-
tion of adaptive immunity. Innate immunity receptors,
called pattern-recognition receptors (PRRs), recognize
a few highly conserved structures on microorganisms
called pathogen-associated molecular patterns (PAMPs).
PRRs are either expressed on cell surface or secreted
and present in body fluids. There are two functionally
different classes of cell surface PRRs: endocytic PRRs
(i.e., scavenger receptors and mannose receptors) in-
volved in the binding and uptake of pathogen compo-
nents and signaling PRRs (members of the Toll-like re-
ceptor [TLR] family) involved in cell activation upon
contact with pathogens. The humoral arm of the innate
immunity includes collectins and pentraxins (Gordon,
2002; Medzhitov, 2001; O’Neill, 2003).
Pentraxins are a superfamily of proteins usually char-
acterized by a pentameric structure and are highly con-
served during evolution (Garlanda et al., 2005; Manto-
vani et al., 2003; Pepys and Hirschfield, 2003; Szalai
et al., 1999). The classical short pentraxins C-reactive
protein (CRP) and serum amyloid P component (SAP)
are acute phase proteins in man and mouse, respec-
tively (Baumann and Gauldie, 1994; Pepys and Baltz,
1983). They are produced in the liver in response to
inflammatory mediators, most prominently IL-6. CRP
and SAP bind, in a calcium-dependent manner, dif-
ferent ligands, and they are involved in the innate resis-
tance to microbes and the scavenging of cellular debris
and extracellular matrix components (Pepys and
Hirschfield, 2003; Szalai et al., 1999). Long pentraxins
are characterized by an unrelated N-terminal domain
coupled to a pentraxin-like C-terminal domain (Gar-
landa et al., 2005; Mantovani et al., 2003). The prototypic
long pentraxin PTX3 is rapidly produced and released by
diverse cell types, in particular by mononuclear phago-
cytes, DCs, and endothelial cells (Breviario et al., 1992;
Doni et al., 2003; Lee et al., 1993; Vidal Alles et al.,
1994), in response to primary inflammatory signals
(e.g., TLR engagement, TNFα, and IL-1). PTX3 binds
with high affinity the complement component C1q, the
extracellular matrix protein TSG6, and selected micro-
organisms (Bottazzi et al., 1997; Garlanda et al., 2002;
Nauta et al., 2003; Salustri et al., 2004). PTX3 activates
the classical pathway of complement activation and fa-
cilitates pathogen recognition by macrophages and
DCs (Diniz et al., 2004; Garlanda et al., 2002; Nauta et
al., 2003). Recent studies in ptx3-deficient (PTX3−/−)
mice have shown that this molecule plays complex
nonredundant functions in vivo, ranging from the as-
Immunity
552Figure 1. Binding of KpOmpA to the Scavenger Receptors
(A) Maleylated BSA prevents KpOmpA binding to APCs. Macrophages and myeloid DCs were incubated with 2.5 M BSA or mBSA. After 10
min, 0.25 M Alexa488-labeled KpOmpA was added before FACS analysis. Gray histogram corresponds to cells incubated with 0.25 M
Alexa488-labeled TT (and is similar to unlabeled cells).
(B) Ligands of SRs prevent KpOmpA binding to APCs. Myeloid DCs, macrophages, and LOX-1- and SREC-I-transfected CHO cells were
incubated with the indicated molecules for 10 min. Then, Alexa488-labeled KpOmpA was added before FACS analysis. Results are expressed
as percentage of inhibition of binding (mean ± SD, n = 5).
(C) FACS analysis of Alexa488-labeled KpOmpA (white histogram) or flagellin (gray histogram; similar to unlabeled cells) binding to CHO cells
transfected with expression vectors encoding LOX-1, SREC-I, MARCO, SR-A1, CD36, and CLA-1.
(D) FACS analysis of FITC-labeled wild-type (wt) (gray histogram) and OmpA-deficient Escherichia coli (white histogram, unbroken line) binding
to SREC-I- and LOX-1-CHO cells; break line histograms correspond to unlabeled CHO cells.sembly of a hyaluronic acid-rich extracellular matrix i
tand female fertility to innate immunity against diverse
microorganisms (Diniz et al., 2004; Garlanda et al., a
K2002; Salustri et al., 2004; Varani et al., 2002).
Whether and how the cellular and humoral arms of d
ainnate immunity interact in the recognition of the same
microbial moieties remains poorly investigated. In addi- c
etion to LPS, the cell wall of Gram-negative bacteria
contains Omp such as OmpA, porins, and lipoproteins.
OmpA is a class of proteins highly conserved among R
the Enterobacteriaceae family and throughout evolu-
tion that are essential for bacteria integrity and viru- I
Blence (Poolman, 1996). Recent data suggest that OmpA
is a bona fide PAMP. Recombinant OmpA from KpOmpA P
Kbinds to and is internalized by antigen-presenting cells
(APCs) such as macrophages and DCs via a still un- 2
(identified endocytic cell surface receptor(s) and acti-
vates them (Jeannin et al., 2000). 2
mHere, we report that innate immunity against KpOmpAnvolves cellular recognition by the scavenger recep-
ors SREC-I and LOX-1 and TLR2-dependent cellular
ctivation. Activation of cellular innate immunity by
pOmpA is followed by humoral amplification via in-
uction of PTX3, which binds KpOmpA. Analysis of tlr2
nd ptx3 gene-targeted mice supports that both the
ellular and the humoral arms of innate immunity are
ssential for a full response to KpOmpA.
esults
nvolvement of Scavenger Receptors in KpOmpA
inding to APCs
revious data, confirmed here, had shown that
pOmpA binds to human macrophages (Jeannin et al.,
000) (Figure 1A) and peripheral blood myeloid DCs
Figure 1A), but not to NK cells, T cells (Jeannin et al.,
000), and plasmacytoid DCs (data not shown), in a
anner suggesting the existence of KpOmpA binding
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553Figure 2. Role of TLR2 in KpOmpA-Mediated Cellular Activation,
but Not KpOmpA Binding
(A) TLR2 transfection does not upregulate KpOmpA binding. CHO
cells were transfected (unbroken line) or not (dotted line) with an
expression vector encoding TLR2. Top, cells were incubated with a
FITC-labeled anti-TLR2 mAb. Gray histogram corresponds to cells
incubated with the isotypic control mAb and is similar on both cell
types. Bottom, cells were incubated with Alexa488-labeled KpOmpA.
Gray histogram corresponds to cells incubated with labeled TT and
is similar on both cell types.
(B) KpOmpA binds to DCs from TLR2-deficient mice. DCs were
generated from wt (white histogram) or TLR2−/− mice (black). Top,
cells were incubated with different concentrations of KpOmpA, and
IL-6 was quantified in the 16 h-supernatants by ELISA. Bottom,
cells were incubated with Alexa488-labeled KpOmpA before FACS
analysis.
In (A) and (B), results are representative of the mean ± SD of one
out of three experiments.
(C) LOX-1 or SREC-I expression upregulates KpOmpA-mediated
TLR2-dependent IL-8 production. 293 cells were transfected or co-
transfected as described. Left column, cells were incubated with
Alexa488-labeled KpOmpA before FACS analysis. Right column,
cells were incubated with 0.1 M KpOmpA, and IL-8 was quantified
in the 10 h-supernatants by ELISA. Results are expressed in MFI
and pg/ml, respectively (mean ± SD, n = 3).Figure 3. TLR2-Dependent Induction of PTX3 Production by
KpOmpA
(A) KpOmpA induces PTX3 mRNA expression. PTX3 mRNA expres-
sion was evaluated by Northern blotting in PBMC from two donors
after 4 hr stimulation with 100 ng/ml LPS or 0.002–0.5 M KpOmpA.
Expression of β-actin was used as internal transcript control.
(B) KpOmpA induces PTX3 production by APCs. PTX3 protein
levels (mean ± SEM) produced by human monocytes (huMo), hu-
man DCs (huDC), and murine DCs (muDC) stimulated for 24 hr with
different concentrations of KpOmpA were quantified by ELISA.
(C) PTX3 production in response to KpOmpA is TLR2 dependent.
PTX3 protein production by murine DCs from wt and TLR2−/− mice
stimulated for 16 hr with KpOmpA was quantified by ELISA. Results
are expressed as mean ± SEM.molecules on APCs (Jeannin et al., 2000). Surprisingly,
maleylated BSA (mBSA), a ligand for numerous SRs
(Abraham et al., 1995), prevented KpOmpA binding to
macrophages and, to a lower extent, to DCs (96% ±
10% and 42% ± 10% inhibition, respectively; mean ±(D) KpOmpA induces TLR2 and LOX-1 colocalization. Immature hu-
man DCs layered on gelatin-coated slides were incubated (right) or
not (left) with 0.5 M KpOmpA for 20 min at 37°C and then with
FITC-labeled anti-LOX-1 mAb and Cy3-labeled anti-TLR2 mAb. Af-
ter washing, cells were fixed with 2% PFA and examined by using
an LSM510 inverted confocal microscope.
Immunity
554Figure 4. Specific Binding of PTX3 to
KpOmpA
(A) The binding of 50–100 nM biotin-labeled
PTX3 (bPTX3) to different concentrations of
KpOmpA immobilized on plastic wells was
analyzed by ELISA.
(B) Binding of 100 nM bPTX3 to exotoxin A,
MDP, TSST, KpOmpA, enterotoxin A and B,
OMV isolated respectively from K. pneumon-
iae, E. coli Omp+, and E. coli Omp− immobi-
lized on plastic wells (1 g/well).
In (A) and (B), the results are presented as
O.D. 405 nm (mean ± SD, n = 3).
(C) Fitting analysis of PTX3-KpOmpA in-
teraction. KpOmpA was immobilized on
plastic wells and incubated with different
amounts of bPTX3. Specific binding was
measured in accordance with a standard
curve of bPTX3, and nonlinear fitting analy-
sis was performed with GraphPad Prism
3.0a software.
(D) Real-time biomolecular study of KpOmpA-
PTX3 interaction. KpOmpA (2.8 M) was in-
jected over a flow cell of a BIAcore F1 sensor
chip containing BSA or PTX3. The overlay of
sensograms after blank subtraction showing
the binding of KpOmpA to immobilized PTX3
are presented.
(E) PTX3 binding to KpOmpA is Ca2+ depen-
dent. Binding of PTX3 to immobilized
KpOmpA was performed in the presence or
absence of 10 mM EGTA. Results are pre-
sented as mean O.D. 405 nm ± SD.
(F) Binding of PTX3 to Klebsiella pneumon-
iae and Burkholderia cepacia. 108 bacteria
were incubated with 100 nM bPTX3 and then
with FITC-labeled streptavidin before FACS
analysis. Gray histograms correspond to
bacteria incubated with FITC-streptavidin
alone.SD, n = 5) (Figure 1A). SRs are cell surface glycopro- i
ateins that bind modified lipoproteins (such as oxidized
[Ox-] and acetylated [Ac-]LDL) and a broad spectrum p
Lof structurally unrelated ligands (Dhaliwal and Stein-
brecher, 1999; Peiser and Gordon, 2001). Ox-LDL, Ac- l
mLDL, and fucoidan, but not BSA (used as a negative
control), also significantly prevented KpOmpA binding
2to APCs (Figure 1B). Collectively, these data suggest
that SRs could be cell surface-capturing receptors for h
uKpOmpA.
b
fLOX-1 and SREC-I Are Receptors for KpOmpA
Expressed on APCs m
fIn order to identify the SRs that bind KpOmpA, Chinese
hamster ovary (CHO) cells were transfected with cDNA i
Eencoding different SRs. KpOmpA bound to LOX-1- and
SREC-I-transfected CHO cells (MFI = 1835 ± 168 and p
t820 ± 86, respectively; mean ± SD, n = 5), but not to
the other SR tested (MARCO, SR-A1, CD36, and CLA-1) l
g(Figure 1C). MARCO, SR-A1, CD36, and CLA-1 expres-
sion by CHO cells is shown in Figure S1 available with p
Othis article online. KpOmpA and fluorescent Ac-LDL did
not bind to mock-transfected CHO cells (data not
shown). As controls, other bacterial proteins, labeled R
Tflagellin (Figure 1C) and tetanus toxoid (TT) (data not
shown), did not bind to SR-transfected CHO cells. Ac- i
eLDL and fucoidan significantly inhibited KpOmpA bind-ng to LOX-1-and SREC-I-CHO cells (Figure 1B). In
greement with these results, human macrophages and
eripheral blood myeloid DCs constitutively express
OX-1 (Delneste et al., 2002) and SREC-I (P.J., unpub-
ished data), in contrast to T cells, NK cells, and plas-
acytoid DCs.
The scavenger receptors LOX-1 (Shimaoka et al.,
001) and SREC-I (P.J., unpublished data) support ad-
esion of Gram-negative bacteria. We therefore eval-
ated the role of OmpA in the binding of Gram-negative
acteria to LOX-1 and SREC-I. As recombinant OmpA
rom Escherichia coli binds to SREC-I and LOX-1 in a
anner similar to KpOmpA (data not shown) (OmpA
rom E. coli and Klebsiella pneumoniae share 88%
dentity), we used wild-type (wt) and OmpA-deficient
. coli (Ec OmpA+ and Ec OmpA−) to evaluate this hy-
othesis. LOX-1- and SREC-I-transfected cells retain
he ability to bind FITC-labeled OmpA− E. coli but to a
ower extent than wt bacteria (Figure 1D), thereby sug-
esting that in addition to OmpA, other structures ex-
ressed on bacteria are recognized together with
mpA by LOX-1 and SREC-I.
ole of TLR2 in Signaling, but Not in Binding
he signaling molecule TLR2 has been suggested to be
nvolved in KpOmpA-mediated APC activation (Jeannin
t al., 2000). We therefore tested whether TLR2 could
Cellular and Humoral Innate Immunity
555Figure 5. Effect of PTX3 on KpOmpA-Induced CCL2 Production
(A) CCL2 production was measured in culture supernatants of mu-
rine peritoneal cells stimulated for 24 hr with 0.002–0.25 M
KpOmpA in the presence or absence of 0.2 M PTX3.
(B) Levels of CCL2 produced by murine peritoneal macrophages
stimulated with 0.25 M KpOmpA in the presence or absence of
different concentrations of PTX3 (0.044–1.1 M).
In (A) and (B), CCL2 production was determined by ELISA, and
results representative of one out of four experiments performed are
expressed in ng/ml (mean ± SD).also act as a KpOmpA binding element on the cell sur-
face. TLR2 transfection does not upregulate KpOmpA
binding to CHO cells (Figure 2A). Although they failed
to be stimulated by KpOmpA (Figure 2B, top), DCs from
TLR2−/− mice bind KpOmpA in a way similar to wt cells
(Figure 2B, bottom). Moreover, KpOmpA binding to
LOX-1- or SREC-I-transfected cells is not upregulated
by cotransfection with TLR2 (Figure 2C). However, co-
transfection of TLR2 with LOX-1 or SREC-I renders 293
cells more responsive to a stimulation with KpOmpA
(as assessed by measuring IL-8 production) than TLR2
alone or TLR2 plus CD36 (Figure 2C). TLR4 expression
does not render LOX-1-transfected 293 cells respon-
sive to KpOmpA (Figure 2C). In resting DCs, TLR2 is
associated to the cell membrane, whereas LOX-1 is
mainly localized to the membrane and, to a larger ex-
tent, in intracellular vesicles (Figure 2D, left). Upon con-
tact with KpOmpA, LOX-1 and TLR2 colocalize at the
cell membrane, with the appearance of double-stained
intracellular vesicles (Figure 2D, right). We therefore
evaluated whether SRs may also participate in KpOmpA-
induced cell activation. First, the SR ligand mBSA (1) is
internalized by APCs but does not stimulate them, and
(2) it does not activate 293 cells transfected with LOX-1
(without or with TLRs) (data not shown). Second, the
crosslinking of LOX-1 or SREC-I with specific mAbs
does not stimulate DCs or macrophages (data not
shown). Third, we observed that OmpX, another Omp
that binds to, is internalized by, but does not activate
DCs and macrophages (Maisnier-Patin et al., 2003),
also binds SREC-I- and LOX-1-transfected cells (butnot the other scavenger receptor tested: CD36, CLA-1,
MARCO, and SR-A1) (Figure S2, left). However, in con-
trast to KpOmpA, OmpX does not activate 293 cells
transfected with TLR2 (Figure S2, right), TLR4, or TLR2
plus LOX-1 (data not shown). Together these data show
that the SR-mediated binding and internalization can
occur independently of TLR-mediated activation.
Collectively, these results suggest that the activation
of an innate cellular response by KpOmpA involves the
cooperation of SR and TLR2 for recognition and signal-
ing, respectively.
KpOmpA Induces PTX3 Production via TLR2
We then examined whether KpOmpA interaction with
APCs may modulate soluble PRR production. KpOmpA,
at concentrations ranging from 0.002 to 0.5 M, in-
duces PTX3 production by human monocytes and DCs,
with a maximal production of 7.3 ± 2.4 (mean ± SEM,
n = 4) and 26.8 ± 8.4 ng/ml (n = 7), respectively (Figures
3A and 3B), by acting at the transcriptional level (Figure
3A). A similar induction of PTX3 production is observed
with murine DCs (Figure 3B). The activity of KpOmpA
as a PTX3 inducer was comparable to that of LPS, used
as reference agent (Doni et al., 2003), and is abrogated
when boiled KpOmpA is used (data not shown). As ex-
pected, DCs are better producers of PTX3 than mono-
cytes (Doni et al., 2003). In parallel, the production of
other soluble PRRs such as mannose binding protein
is unaffected (data not shown). Finally, by using DCs
from wt and TLR2−/− mice, we demonstrate that
KpOmpA-induced PTX3 production is TLR2 dependent
(Figure 3C).
PTX3 Binds KpOmpA with High Affinity
As PTX3 is a soluble PRR, we tested whether it may
interact with KpOmpA. PTX3 binds KpOmpA (Figure
4A), but not other microbial moieties tested, some of
which are shown in Figure 4B, with an apparent dissoci-
ation constant (KD) equal to 36 × 10−9 M (Figure 4C).
By using the BIAcore technology, an association rate
constant (kon) equal to 1.77 × 104 M−1 s−1 and a dissoci-
ation rate constant (koff) equal to 8.57 × 10−4 s−1, with
an estimated KD equal to 50 × 10−9 M, comparable to
that estimated by conventional binding, were obtained
(Figure 4D). Although the interaction of PTX3 with C1q
is Ca2+-independent, PTX3 binding to KpOmpA was
Ca2+ dependent (Figure 4E). PTX3 binds Klebsiella
pneumoniae (Figure 4F) and a protein extract obtained
from outer membrane vesicles (OMVs) of Klebsiella
pneumoniae (Figure 4B), but not Burkholderia cepacia
used as irrelevant control (Figure 4F). In addition, it
binds more efficiently OMVs of OmpA+ E. coli than
OMVs of OmpA− E. coli (Figure 4B), as well as intact
OmpA+ versus OmpA− E. coli (data not shown).
PTX3 Does Not Modulate KpOmpA
Recognition by APCs
Soluble cytokines (e.g., IL-6 receptor α chain) (Romano
et al., 1997) or PRRs (e.g., CD14) can present ligands
to membrane bound receptor moieties and activate sig-
naling. We therefore tested whether KpOmpA recogni-
tion by PTX3 may activate a trans-signaling cascade or
affect KpOmpA interaction with APCs. Cells were ex-
Immunity
556Figure 6. In Vivo Role of TLR2 and PTX3 in
KpOmpA-Induced Inflammation
(A and B) Role of TLR2 in KpOmpA-induced
inflammation. KpOmpA or BSA were injected
into the footpad of wt and TLR2−/− mice. At
different time points, footpad swelling was
measured (A) and inguinal LNs were excised
and LN cells counted (B). Results are mean ±
SD of three separate experiments.
(C) Inflammatory response to KpOmpA in
PTX3−/− mice. PTX3−/− and wt mice were in-
jected into the footpad with KpOmpA (0.625
nmol), and footpad swelling was measured.
Results are mean ± SEM (n = 8) and are re-
presentative of two experiments.
(D) Reconstitution of the inflammatory re-
sponse in PTX3−/− mice. PTX3−/− mice were
injected with KpOmpA (0.5 nmol) and treated
with 0.55 nmol PTX3 coadministered in the
footpad. Results are mean ± SEM (n = 8; one
experiment performed). *p = 0.01, **p = 0.03
(Student’s t test).
(E) PTX3 amplifies the inflammatory re-
sponse to KpOmpA. Mice were injected in
the air pouch with PBS, KpOmpA (0.625
nmol), PTX3 (0.55 nmol), or KpOmpA + PTX3
and sacrificed after 4 or 24 hr. The pouch
fluid (1 ml) was collected, and total cells
were counted. Results are mean ± SEM. *p =
0.003, **p = 0.04 (Student’s t test).posed to KpOmpA in the presence of PTX3, and bind- K
cing and cytokine production were measured. PTX3
u(0.044–1.1 M) does not affect KpOmpA-induced
P(0.002–0.25 M) CCL2 production by murine peritoneal
tmacrophages (Figure 5). At concentrations exceeding
s1.1 M, a modest inhibition (30% in two independent
mexperiments) was observed (data not shown). In addi-
mtion, PTX3 does not modulate KpOmpA-induced IL-8
iand TNFα production by human DCs nor DC maturation
t(data not shown). In agreement with these observa-
Ftions, PTX3 did not affect binding of KpOmpA to TLR2-,
PLOX-1-, or SREC-I-transfected cells (data not shown).
dAccordingly, KpOmpA-elicited IL-8 production by
mTLR2-transfected cells was unaffected by PTX3. Finally,
mexogenous PTX3 did not modify the responsiveness of
pcells from PTX3−/− mice to KpOmpA in terms of chemo-
nkine production (not shown), thus ruling out that the
F
apparent lack of effects of exogenous PTX3 is in fact
P
due to endogenous saturating production of this m
molecule. j
w
In Vivo Relevance P
The above results indicate that KpOmpA is recognized i
by the cellular SRs SREC-I and LOX-1 and activates h
cells via TLR2. In an effort to examine the actual in vivo T
relevance of TLR2, we measured the inflammatory ac- m
stivity of KpOmpA in TLR2−/− mice. In response topOmpA, footpad swelling and lymph node (LN) cell
ounts are dramatically reduced in TLR2−/− mice (Fig-
res 6A and 6B). KpOmpA induces the production of
TX3, which in turn binds to KpOmpA. We therefore
ested the in vivo relevance of this interaction by mea-
uring the inflammatory response to KpOmpA in PTX3−/−
ice. After KpOmpA injection in the footpad, PTX3−/−
ice showed a significant reduction of footpad swell-
ng at early time points (44% reduction at 2 hr, p = 0.01,
wo experiments performed) (Figure 6C). As shown in
igure 6D, in a third experiment, exogenous injection of
TX3 together with KpOmpA abrogated the 56% re-
uction in inflammation observed in PTX3-deficient
ice at the time of maximal reduction relative to wt
ice (2 hr) and reduced the difference at later time
oints. Injection of PTX3 subcutaneously per se does
ot elicit an inflammatory response (data not shown).
inally, in an effort to further explore the capacity of
TX3 to amplify the response to KpOmpA, an air pouch
odel was used. As shown in Figure 6E, KpOmpA in-
ection caused a leukocyte recruitment in the pouch,
hereas PTX3 alone was inactive. When KpOmpA and
TX3 are coinjected in the pouch, a 145% and 85%
ncrease in leukocyte counts is observed at 4 and 24
r, respectively (p = 0.003 and p = 0.04, respectively).
hus, PTX3 inoculation represents a nonredundant hu-
oral amplification loop of the local inflammatory re-
ponse elicited by KpOmpA.
Cellular and Humoral Innate Immunity
557Discussion
OmpA is a major outer membrane protein of Gram-
negative Enterobacteriaceae. OmpA includes an N-ter-
minal eight transmembrane amphipatic region located
in the outer membrane and a C-terminal portion in the
periplasm. Conservation of OmpA is high among mem-
bers of the Enterobacteriaceae family and in evolution.
Evidence indicates that OmpA plays an essential role
in bacterial structural integrity and is a determinant of
bacterial virulence (Poolman, 1996). These properties
are consistent with the general characteristics of sev-
eral microbial moieties recognized by innate immunity
receptors (Janeway and Medzhitov, 2002). The results
reported here demonstrate that KpOmpA is recognized
by a complex set of cellular and humoral PRRs.
Cellular recognition of KpOmpA is mediated by two
members of the SR family, LOX-1 and SREC-I, ex-
pressed on macrophages and DCs. This conclusion is
based on several lines of evidence, including competi-
tion with known SR ligands and gene transfer. In agree-
ment with, and as an extension of, previous data (Jean-
nin et al., 2000), we found that TLR2 was dispensable
for binding but absolutely required for cellular activa-
tion by KpOmpA. LOX-1 and TLR2 colocalize upon ex-
posure of cells to KpOmpA, and coexpression facili-
tates TLR2-dependent cellular activation by KpOmpA.
Collectively, these results suggested that SR act in a
sequential and coordinate way with TLR to mediate
OmpA internalization and OmpA-mediated activation.
TLR2 appears as the main transducing molecule in-
volved in KpOmpA-mediated activation even though
we cannot exclude that SRs may, under some condi-Figure 7. Schematic Representation of the Complexity and Com-
plementarity of Cellular and Humoral Innate Immune Responses
to KpOmpAtions, potentiate the activation signal. Recent studies
showed that β glucan, a yeast cell wall component, is
recognized by Dectin-1 but that cellular activation re-
quires TLR2 (Brown et al., 2003; Gantner et al., 2003).
Recognition of and activation by KpOmpA involves a
similar cooperative interaction between members of
the SR family and TLR2.
The genetic program activated by KpOmpA in macro-
phages or DCs includes induction of the long pentraxin
PTX3. PTX3 is a soluble PRR that interacts with fungi
and bacteria (Diniz et al., 2004; Garlanda et al., 2005;
Garlanda et al., 2002). Moreover, it binds the extracellu-
lar matrix protein TSG6 and has a key role in the assem-
bly of a hyaluronic acid-rich extracellular matrix (Sal-
ustri et al., 2004). PTX3 plays a nonredundant role
against selected pathogens, including Aspergillus fumi-
gatus and Pseudomonas aeruginosa (Garlanda et al.,
2002). The results reported here show that PTX3,
whose production is induced by KpOmpA and by in-
flammatory signals (e.g., LPS, IL-1, and TNFα), binds
KpOmpA with high affinity.
Soluble receptors can present agonists to mem-
brane-anchored signaling receptors and be part of sig-
naling receptor complexes, as exemplified by CD14
and MD2 for TLR4 and the soluble IL-6 receptor α chain
for IL-6 (Romano et al., 1997). It was therefore impor-
tant to assess whether soluble PTX3 could act as a
component of cellular signaling receptor complexes,
which recognize KpOmpA. PTX3 did not amplify or
block the responsiveness of macrophages or DCs to
KpOmpA, and cells from PTX3−/− mice responded nor-
mally to KpOmpA. Thus, PTX3 represents a bona fide
humoral KpOmpA-recognizing molecule and it does not
interact with cellular receptors, which bind this bacte-
rial component.
When given subcutaneously, i.v., or i.p., PTX3 had
essentially no inflammatory activity per se (Garlanda et
al., 2005 and data not shown). However, when adminis-
tered with KpOmpA, PTX3 significantly amplified the in-
flammatory response elicited by this microbial moiety
(Figure 6E). Moreover, PTX3−/− showed a significant
reduction (20%–50% at early time points) of local in-
flammation elicited by KpOmpA. Thus, PTX3 acts as a
nonredundant humoral amplification system of the re-
sponse elicited by KpOmpA. PTX3 is the only element
of the cascade of mediators (cytokines, chemokines,
etc…) set in motion by TLR2-dependent activation of
innate immunity by KpOmpA. The finding that PTX3 ac-
counts for 40%–50% of the inflammatory response at
early time points is fully consistent with it being a non-
redundant amplification loop in the cascade, in con-
trast to TLR2, which sets in motion the whole cascade
and whose deficiency essentially abrogates the re-
sponse.
PTX3 binds C1q and activates the complement cas-
cade (Nauta et al., 2003). Moreover, a cellular PTX3
binding site expressed on macrophages and DCs has
been identified. PTX3 binding facilitates recognition
and ingestion of conidia and zymosan (Diniz et al.,
2004; Garlanda et al., 2002). The relative importance of
these two pathways in the role played by PTX3 in the
inflammatory response to KpOmpA remains to be de-
termined.
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558iThe innate immune system consists of a cellular and
Ga humoral arm, a general organization reminiscent of
Cadaptive immunity. The studies reported here highlight
C
the complexity and complementarity of cellular and hu- 1
moral recognition of KpOmpA (Figure 7). KpOmpA is u
recognized by cellular receptors, which include SRs
H(LOX-1 and SREC-I) for binding and TLR2 for signaling.
PCellular recognition of KpOmpA activates a proinflam-
ematory program that includes the humoral PRR PTX3,
(which in turns binds this microbial moiety. Cellular and
I
humoral (PTX3-mediated) recognition of KpOmpA are e
complementary in mediating the innate response to this g




fCell Culture Media and Reagents
mThe following reagents were used for tissue culture: pyrogen-free
Csaline (SALF, Bergamo, Italy); phosphate-buffered saline (PBS) with
calcium and magnesium (Bio Whittaker, Walkersville, MD); RPMI
M1640, L-glutamine, and Ficoll Hypaque (Biochrom, Berlin, Ger-
Tmany); and aseptically collected fetal calf serum (FCS; HyClone
wLaboratories, Logan, UT). All reagents contained <0.125 endotoxin
PU/ml, as determined by the Limulus amebocyte lysate assay (Bio
wWhittaker). Lipopolysaccharide (LPS) from Escherichia coli strain
o055:B5 was obtained from Difco Laboratories (Detroit, MI). Bovine
cserum albumin (BSA), with low endotoxin characteristics, exotoxin
cA from Pseudomonas aeruginosa, toxic shock syndrome toxin
n(TSST), and enterotoxin A and B from Staphylococcus aureus and
pN-acetylmuramyl-L-alanyl-D-isoglutamine (MDP) were from Sigma-
Aldrich (St. Louis, MO). GM-CSF was a gift from Novartis (Milan,
TItaly); M-CSF and murine GM-CSF were from R&D Systems (Ab-
Cingdon, UK).
CRecombinant human PTX3 was purified from CHO cells constitu-
ctively expressing the protein as described (Bottazzi et al., 1997).
pBiotinylated PTX3 (bPTX3) was obtained following standard proto-
(cols. Recombinant KpOmpA expression and purification were per-
(formed as described (Jeannin et al., 2000) with the following final
Dadditional steps. Briefly, after ethanol precipitation and solubiliza-
ption in 7 M urea, KpOmpA was submitted to size exclusion chroma-
Ltography in water. Purification was carried out in apyrogenic condi-
Ctions. KpOmpA batches used were produced according to
upharmaceutical quality standards intended for clinical trials in hu-
tman. Endotoxin contamination was <0.25 EU/mg of KpOmpA (Lim-
uulus amebocyte lysate assay) and was also excluded by using cells
pfrom tlr4-deficient mice (Jeannin et al., 2000). Lipoprotein contami-
Ination was excluded by the extensive characterization of contami-
nating traces of proteins present in KpOmpA batches (Haeuw and
Beck, 2004). OmpX expression and purification was performed as P
described (Jeannin et al., 2000). TT was purchased from SBL vac- M
cine (Stockholm, Sweden); endotoxin contamination checked by s
the limulus assay test was <0.25 EU/mg of proteins. KpOmpA and c
TT were labeled with Alexa488 as described by the manufacturer e
(Molecular Probes, Eugene, OR). f
Wt and OmpA-deficient Escherichia coli (kindly provided by Dr. t
A. Robert, Centre d’Immunologie Pierre Fabre, F-Saint-Julien en e
Genevois) were labeled with FITC as described (Van den Berg et f
al., 1999) and UV irradiated. Burkholderia cepacia and Klebsiella N
pneumoniae were from clinical isolates kindly provided by Dr. M. m
Conese (H.S. Raffaele, Milan) and by Dr. E. De Vecchi (L. Sacco e
Teaching Hospital, Milan), respectively. The method for preparation a
of membrane fractions from outer membrane vesicles extracted [
from K. pneumoniae, E. coli OmpA+, and E. coli OmpA− was u
adapted from Davies et al. (1990).
B
BMice
129/sv mice were from Charles River (Calco, Italy), ptx3-deficient v
(mice were generated as described (Garlanda et al., 2002). C57Bl/6
(H-2b) mice were from Harlan (Gannat, France). C57Bl/6 tlr2 knock- p
rout (TLR2−/−) have been previously described (Takeuchi et al.,
1999). Procedures involving animals and their care conformed to bnstitutional guidelines in compliance with national (4D.L. N.116,
.U., suppl. 40, 18-2-1992) and international law and policies (EEC
ouncil Directive 86/609, OJ L 358,1,12-12-1987; NIH Guide for the
are and Use of Laboratory Animals, US National Research Council
996). All efforts were made to minimize the number of animals
sed and their suffering.
uman Cells
eripheral blood mononuclear cells (PBMC) were purified under
ndotoxin-free conditions from fresh buffy coats of healthy donors
courtesy of the Centro Trasfusionale, Ospedale Niguarda, Milan,
taly) by Ficoll gradients. Monocytes were purified by Percoll gradi-
nts (Amersham Biosciences, Uppsala, Sweden), and DCs were
enerated from monocytes as described (D’Amico et al., 1998; Pie-
onti et al., 1995). Human BDCA-1+, CD11chigh, and CD123low
lood myeloid DCs were isolated by using magnetic beads per the
anufacturer’s instructions (Miltenyi Biotech, Bergish Gladbach,
ermany). Macrophages were generated by culturing monocytes
or 5 days in RPMI 1640 medium supplemented with 2 mM L-gluta-
ine, 10% FCS, and antibiotics (cRPMI) containing 2 ng/ml GM-
SF and 20 ng/ml M-CSF.
urine Cells
o obtain peritoneal exudate cells (PECs), mice were injected i.p.
ith 1 ml of 3% thioglycollate medium (Difco Laboratories), and
ECs were harvested after 4 days by washing the peritoneal cavity
ith 5 ml saline. PECs collected in that way contain more than 80%
f macrophages, as determined by morphological evaluation on
ytospin. Murine DCs were generated by culturing bone marrow
ells in cRPMI supplemented with 50 M β-mercaptoethanol and 3
g/ml murine GM-CSF. At day 5, nonadherent immature DCs ex-
ressing intermediate levels of I-A were used.
ransfectants
HO cells transfected with LOX-1, CD36, MARCO, SRA-1, and
LA-1 were generated as described (Delneste et al., 2002). The
DNA-encoding SREC-I was subcloned in the expression vector
CDNA3.1 containing a sequence encoding the protein C tag
EDQVDPRLIDGK) in frame with the inserted sequence. CHO cells
ATCC, Manassas, VA) were transfected by using Fugene-6 (Roche
iagnostic, Meylan, France) and cultured in ISCOVE medium sup-
lemented with 10% FCS and selected with hygromycin (all from
ife Technologies) before clones were picked. SREC-I-, SRA-1-,
D36-, and CLA-1-expressing cells were isolated by FACS sorting
sing 5 g/ml fluorescent DiI-Ac-LDL (Harbor Bioproducts, Stroug-
hon, MA). LOX-1- and MARCO-expressing cells were sorted by
sing anti-LOX-1 (clone 23C11) (Delneste et al., 2002) and anti-tag
rotein C mAb, respectively, revealed with FITC-labeled anti-mouse
g (Silenus, Melbourne, Australia).
TX3 Protein and Transcript Levels
onocytes and DCs were cultured for 24 hr in RPMI 1640 medium
upplemented with 2 mM L-glutamine and 0.2% BSA at 1 × 106
ells/well/ml in 24-well tissue culture plates (Falcon; BD Biosci-
nces, Franklin Park, NJ) in the presence of 100 ng/ml LPS or dif-
erent concentrations of KpOmpA. PTX3 levels in culture superna-
ants were quantified by ELISA as described (Peri et al., 2000). To
valuate PTX3 mRNA induction, cells were stimulated as described
or 4–6 hr in 50 ml tubes (Falcon; BD Biosciences). Total RNA for
orthern analysis was extracted by the guanidine isothiocyanate
ethod, blotted, and hybridized as previously described (Breviario
t al., 1992). Human full-length cDNA for PTX3 was used as probe
nd labeled by using the Megaprime DNA labeling system with
32P]dCTP (3000 Ci/mmol; Amersham Biosciences). β-actin was
sed as internal transcript control.
inding Assay
inding of PTX3 to KpOmpA was performed essentially as pre-
iously described (Bottazzi et al., 1997). Briefly, 96-well plates
Nunc, Roskilde, Denmark) were coated overnight with 1–5 g of
urified KpOmpA and blocked with 0.5% dry milk in PBS (2 hr at
oom temperature) before incubation (30 min, 37°C) with 100 l of
PTX3 (50–100 nM considering a molecular weight of 45 kDa for
Cellular and Humoral Innate Immunity
559the PTX3 monomer) in PBS containing 0.05% Tween 20 (PBST).
After washing, plates were incubated with HRP-labeled avidin
(Bio-spa, Milan, Italy), and absorbance values were read at 405 nm
after addition of the chromogen substrate ABTS (Kirkegaard and
Perry, Gaithersburg, MD). Binding of bPTX3 to exotoxin A, MDP,
TSST, enterotoxin A and B, OMV from K. pneumoniae, Omp− E. coli,
and Omp+ E. coli (1 g/well) was analyzed with the same protocol.
To characterize the specific binding, bPTX3 (0.56–17.92 pmol) was
added to triplicate wells coated with 125 pmol/well of KpOmpA,
and bound PTX3 was detected as described above. The results
were converted to picomolar concentration by using a standard
curve of bPTX3. Kd and Bmax were obtained by nonlinear fitting of
the saturation curves by means of GraphPad Prism 3.0a software.
In a different set of experiments, a BIAcore X apparatus (BIAcore,
Piscataway, NJ) was used. Surface plasmon resonance (SPR) was
exploited to measure changes in refractive index caused by the
ability of free KpOmpA to bind to PTX3 immobilized to a BIAcore
sensorchip. To this purpose, purified human PTX3 (2.2 M) was
allowed to react with a flow cell of a F1 sensorchip that was pre-
viously activated with 50 l of 0.2 M N-ethyl-N,-(3-diethylaminopro-
pyl)carbodiimide hydrochloride (EDC) and 0.05 M N-hydroxysuc-
cinimide (NHS). These experimental conditions allowed the
immobilization of 670 resonance units (RU), corresponding to w15
fmoles/mm2 of PTX3. A F1 sensorchip to which BSA was immobi-
lized was used as a blank control. Increasing concentrations of
KpOmpA in 10 mM HEPES, 150 mM NaCl, 3.4 mM EDTA, 0.005%
surfactant P20, and pH 7.4 (HBS) were injected over the BSA- or
PTX3-coated surfaces for 4 min and then washed until dissociation
was observed. The SPR signal was expressed in terms of RU. PTX3
binding to bacteria was performed as previously described (Gar-
landa et al., 2002).
Cytokine Production
Murine CCL2 levels were measured by ELISA (Peri et al., 1994) in
24 hr cell-free supernatants from PEC (1 × 106/ml in 96-well plates)
cultured in cRPMI in the presence of 0.002–0.25 M KpOmpA with-
out or with different concentrations of PTX3. Murine IL-6 was quan-
tified by ELISA (R&D Systems) in the 16 hr cell-free supernatants
of DCs from wt versus TLR2−/− mice cultured in cRPMI at 106 cells/
ml in 96-well tissue culture plates and exposed or not to 0.06–0.5
M KpOmpA. Human IL-8 was quantified by ELISA (R&D Systems)
in the 10 hr supernatants of 293 cells in RPMI (without FCS) ex-
posed to 0.1 M KpOmpA.
Flow Cytometry
Flow cytometry analysis was performed by using a FACSvantage
cytofluorometer (Becton Dickinson, San Jose, CA). 2 × 105 cells/
well in 96-V-bottom-well plates were incubated for 20 min either at
4°C in FACS buffer (0.1% BSA in RPMI 1640 medium) with 0.5 M
Alexa488-labeled KpOmpA or TT or at RT with 5 g/mL FITC-
labeled bacteria. In neutralization experiments, cells were or were
not preincubated with BSA, maleylated BSA, Ox- or Ac-LDL (both
from Biogenesis, Poole, UK), or fucoidan (Sigma-Aldrich) for 10 min
at 4°C before incubation with Alexa488-labeled KpOmpA. Results
are in MFI or as a percentage of inhibition as follows: A-B/A × 100
where A and B are the MFI values in the absence or presence of
the unlabeled molecule, respectively.
Mice Inoculation
Wt and TLR2−/− mice were injected subcutaneously with 0.625
nmol BSA or KpOmpA. At different time points, inguinal lymph
nodes were excised and LN cells were counted as previously de-
scribed (Jeannin et al., 2003). For footpad swelling, PTX3−/−, TLR2−/−,
and control mice were injected subcutaneously in the footpads
with PBS or 0.625 nmol KpOmpA in PBS. In the reconstitution ex-
periments, wt and PTX3−/− mice were injected with 0.5 nmol
KpOmpA alone or preincubated with 0.44 nmol PTX3. At different
time points, foot swelling was measured with a calliper. The air
pouch model was used as described (Romano et al., 1997). Briefly,
mice were injected with PBS, 0.625 nmol KpOmpA, 0.55 nmol
PTX3, or 0.625 nmol KpOmpA preincubated with 0.55 nmol PTX3.
At 4 or 24 hr after treatment, animals were anesthetized, thepouches were washed with 1 ml of saline, and total cells were
counted.
Confocal Microscopy
Anti-LOX-1 (Delneste et al., 2002) and anti-TLR2 mAbs (eBio-
science, San Diego, CA) were labeled with FITC and Cy3, respec-
tively, by using commercial kits (Sigma-Aldrich and Amersham
Biosciences, respectively). Myeloid DCs were cultured on gelatin-
coated slides for 2 hr at 37°C, washed with PBS and incubated
with 0.5 M KpOmpA or not for 20 min at 37°C, washed in PBS
and incubated for 30 min with 5 g/ml FITC-labeled anti-LOX-1
mAb and 5 g/ml Cy3-labeled anti-TLR2 mAb in PBS-BSA for 30
min. After washing, cells were fixed with 4% PFA, mounted with
fluorescent mounting medium (DakoCytomation, Glostrup, Den-
mark) and examined by using a LSM510 inverted confocal micro-
scope (Zeiss, Oberkochen, Germany).
Statistical Analysis
Statistical analysis was performed by using the Student’s t test. To
estimate the KD (i.e., the equilibrium dissociation constant) binding
of PTX3 to plastic immobilized KpOmpA was analyzed by nonlinear
fitting using the equation of the “one site binding curve” (GraphPad
Prism 3.0a software, GraphPad, San Diego, CA).
Supplemental Data
Supplemental Data include two figures and are available with this
article online at http://www.immunity.com/cgi/content/full/22/5/
551/DC1/.
Acknowledgments
We are grateful to A. Bugatti for the BIAcore analysis and to Dr K.
Maisnier-Patin for the data with OmpX. This work was supported
by the Italian Association for Cancer Research (AIRC), by the Euro-
pean Commission (project MUGEN, DC-Thera), and by Ministero
dell'Istruzione, Università e Ricerca. A.M., C.G., B.B., M.R., and
M.P. are inventors in patent applications concerning PTX3. During
part of this work, P.J. was an employee of Pierre Fabre; G.M., J.P.H.,
G.H., and N.C. are employees of Pierre Fabre. The authors have no
other financial interest in this work.
Received: September 10, 2004
Revised: February 14, 2005
Accepted: March 9, 2005
Published: May 17, 2005
References
Abraham, R., Singh, N., Mukhopadhyay, A., Basu, S.K., Bal, V., and
Rath, S. (1995). Modulation of immunogenicity and antigenicity of
proteins by maleylation to target scavenger receptors on macro-
phages. J. Immunol. 154, 1–8.
Baumann, H., and Gauldie, J. (1994). The acute phase response.
Immunol. Today 15, 74–80.
Bottazzi, B., Vouret-Craviari, V., Bastone, A., De Gioia, L.,
Matteucci, C., Peri, G., Spreafico, F., Pausa, M., D’Ettorre, C., Gia-
nazza, E., et al. (1997). Multimer formation and ligand recognition
by the long pentraxin PTX3. Similarities and differences with the
short pentraxins C-reactive protein and serum amyloid P compo-
nent. J. Biol. Chem. 272, 32817–32823.
Breviario, F., d’Aniello, E.M., Golay, J., Peri, G., Bottazzi, B., Bai-
roch, A., Saccone, S., Marzella, R., Predazzi, V., Rocchi, M., et al.
(1992). Interleukin-1-inducible genes in endothelial cells. Cloning
of a new gene related to C-reactive protein and serum amyloid P
component. J. Biol. Chem. 267, 22190–22197.
Brown, G.D., Herre, J., Williams, D.L., Willment, J.A., Marshall, A.S.,
and Gordon, S. (2003). Dectin-1 mediates the biological effects of
beta-glucans. J. Exp. Med. 197, 1119–1124.
D’Amico, G., Bianchi, G., Bernasconi, S., Bersani, L., Piemonti, L.,
Sozzani, S., Mantovani, A., and Allavena, P. (1998). Adhesion, trans-
Immunity
560endothelial migration, and reverse transmigration of in vitro cul- O
itured dendritic cells. Blood 92, 207–214.
3Davies, R.L., Wall, R.A., and Borriello, S.P. (1990). Comparison of
Pmethods for the analysis of outer membrane antigens of Neisseria
tmeningitidis by western blotting. J. Immunol. Methods 134, 215–
i225.
PDelneste, Y., Magistrelli, G., Gauchat, J., Haeuw, J., Aubry, J., Naka-
cmura, K., Kawakami-Honda, N., Goetsch, L., Sawamura, T.,
aBonnefoy, J., and Jeannin, P. (2002). Involvement of LOX-1 in den-
dritic cell-mediated antigen cross-presentation. Immunity 17, 353– P
362. i
Dhaliwal, B.S., and Steinbrecher, U.P. (1999). Scavenger receptors P
and oxidized low density lipoproteins. Clin. Chim. Acta 286, 191– S
205. b
pDiniz, S.N., Nomizo, R., Cisalpino, P.S., Teixeira, M.M., Brown, G.D.,
EMantovani, A., Gordon, S., Reis, L.F., and Dias, A.A. (2004). PTX3
ofunction as an opsonin for the dectin-1-dependent internalization
of zymosan by macrophages. J. Leukoc. Biol. 75, 649–656. P
FDoni, A., Peri, G., Chieppa, M., Allavena, P., Pasqualini, F., Vago, L.,
PRomani, L., Garlanda, C., and Mantovani, A. (2003). Production of
mthe soluble pattern recognition receptor PTX3 by myeloid, but not
plasmacytoid, dendritic cells. Eur. J. Immunol. 33, 2886–2893. P
AGantner, B.N., Simmons, R.M., Canavera, S.J., Akira, S., and Un-
tderhill, D.M. (2003). Collaborative induction of inflammatory re-
Gsponses by dectin-1 and Toll-like receptor 2. J. Exp. Med. 197,
1107–1117. P
TGarlanda, C., Hirsch, E., Bozza, S., Salustri, A., De Acetis, M., Nota,
RR., Maccagno, A., Riva, F., Bottazzi, B., Peri, G., et al. (2002). Non-
Gredundant role of the long pentraxin PTX3 in anti-fungal innate im-
emune response. Nature 420, 182–186.
cGarlanda, C., Bottazzi, B., Bastone, A., and Mantovani, A. (2005).
SPentraxins at the crossroad between innate immunity, inflamma-
Btion, matrix deposition, and female fertility. Annu. Rev. Immunol. 23,
a337–366.
oGordon, S. (2002). Pattern recognition receptors: doubling up for
mthe innate immune response. Cell 111, 927–930.
SHaeuw, J.F., and Beck, A. (2004). Proteomics for development of
Kimmunotherapies. In Proteomics: Biomedical and Pharmaceutical
GApplications, H. Hondermarck, ed. (Dordrecht: Kluwer Academic
5Publisher), pp. 243–278.
SJaneway, C.A., Jr., and Medzhitov, R. (2002). Innate immune re-
(cognition. Annu. Rev. Immunol. 20, 197–216.
f
Jeannin, P., Renno, T., Goetsch, L., Miconnet, I., Aubry, J.P., Del-
Tneste, Y., Herbault, N., Baussant, T., Magistrelli, G., Soulas, C., et
Tal. (2000). OmpA targets dendritic cells, induces their maturation
Tand delivers antigen into the MHC class I presentation pathway.
cNat. Immunol. 1, 502–509.
VJeannin, P., Magistrelli, G., Herbault, N., Goetsch, L., Godefroy, S.,
VCharbonnier, P., Gonzalez, A., and Delneste, Y. (2003). Outer mem-
ibrane protein A renders dendritic cells and macrophages respon-
tsive to CCL21 and triggers dendritic cell migration to secondary
Vlymphoid organs. Eur. J. Immunol. 33, 326–333.
H
Lee, G.W., Lee, T.H., and Vilcek, J. (1993). TSG-14, a tumor necrosis
3
factor- and IL-1-inducible protein, is a novel member of the pen-
f
taxin family of acute phase proteins. J. Immunol. 150, 1804–1812.
V
Maisnier-Patin, K., Malissard, M., Jeannin, P., Haeuw, J.F., Corbiere,
t
J.C., Hoeffel, G., Gauchat, J.F., Nguyen, T., Saez, J.M., and Del-
t
neste, Y. (2003). The outer membrane protein X from Escherichia
3
coli exhibits immune properties. Vaccine 21, 3765–3774.
Mantovani, A., Garlanda, C., and Bottazzi, B. (2003). Pentraxin 3, a
non-redundant soluble pattern recognition receptor involved in in-
nate immunity. Vaccine 21, S43–S47.
Medzhitov, R. (2001). Toll-like receptors and innate immunity. Nat.
Rev. Immunol. 1, 135–145.
Nauta, A.J., Bottazzi, B., Mantovani, A., Salvatori, G., Kishore, U.,
Schwaeble, W.J., Gingras, A.R., Tzima, S., Vivanco, F., Egido, J., et
al. (2003). Biochemical and functional characterization of the in-
teraction between pentraxin 3 and C1q. Eur. J. Immunol. 33, 465–
473.’Neill, L.A. (2003). Therapeutic targeting of Toll-like receptors for
nflammatory and infectious diseases. Curr. Opin. Pharmacol. 3,
96–403.
eiser, L., and Gordon, S. (2001). The function of scavenger recep-
ors expressed by macrophages and their role in the regulation of
nflammation. Microbes Infect. 3, 149–159.
epys, M.B., and Baltz, M.L. (1983). Acute phase proteins with spe-
ial reference to C-reactive protein and related proteins (pentaxins)
nd serum amyloid A protein. Adv. Immunol. 34, 141–212.
epys, M.B., and Hirschfield, G.M. (2003). C-reactive protein: a crit-
cal update. J. Clin. Invest. 111, 1805–1812.
eri, G., Milanese, C., Matteucci, C., Ruco, L., Zhou, D., Sozzani,
., Coletta, I., and Mantovani, A. (1994). A new monoclonal anti-
ody (5D3–F7) which recognizes human monocyte-chemotactic
rotein-1 but not related chemokines. Development of a sandwich
LISA and in situ detection of producing cells. J. Immunol. Meth-
ds 174, 249–257.
eri, G., Introna, M., Corradi, D., Iacuitti, G., Signorini, S., Avanzini,
., Pizzetti, F., Maggioni, A.P., Moccetti, T., Metra, M., et al. (2000).
TX3, A prototypical long pentraxin, is an early indicator of acute
yocardial infarction in humans. Circulation 102, 636–641.
iemonti, L., Bernasconi, S., Luini, W., Trobonjaca, Z., Minty, A.,
llavena, P., and Mantovani, A. (1995). IL-13 supports differentia-
ion of dendritic cells from circulating precursors in concert with
M-CSF. Eur. Cytokine Netw. 6, 245–252.
oolman, J.T. (1996). Bacterial outer membrane protein vaccines.
he meningococcal example. Adv. Exp. Med. Biol. 397, 73–77.
omano, M., Sironi, M., Toniatti, C., Polentarutti, N., Fruscella, P.,
hezzi, P., Faggioni, R., Luini, W., van Hinsbergh, V., Sozzani, S.,
t al. (1997). Role of IL-6 and its soluble receptor in induction of
hemokines and leukocyte recruitment. Immunity 6, 315–325.
alustri, A., Garlanda, C., Hirsch, E., De Acetis, M., Maccagno, A.,
ottazzi, B., Doni, A., Bastone, A., Mantovani, G., Peccoz, P.B., et
l. (2004). PTX3 plays a key role in the organization of the cumulus
ophorus extracellular matrix and in in vivo fertilization. Develop-
ent 131, 1577–1586.
himaoka, T., Kume, N., Minami, M., Hayashida, K., Sawamura, T.,
ita, T., and Yonehara, S. (2001). LOX-1 supports adhesion of
ram-positive and Gram-negative bacteria. J. Immunol. 166,
108–5114.
zalai, A.J., Agrawal, A., Greenhough, T.J., and Volanakis, J.E.
1999). C-reactive protein: structural biology and host defense
unction. Clin. Chem. Lab. Med. 37, 265–270.
akeuchi, O., Hoshino, K., Kawai, T., Sanjo, H., Takada, H., Ogawa,
., Takeda, K., and Akira, S. (1999). Differential roles of TLR2 and
LR4 in recognition of gram-negative and gram-positive bacterial
ell wall components. Immunity 11, 443–451.
an den Berg, B., Beekhuizen, H., Willems, R.J., Mooi, F.R., and
an Furth, R. (1999). Role of Bordetella pertussis virulence factors
n adherence to epithelial cell lines derived from the human respira-
ory tract. Inf Immun 67, 1056–1062.
arani, S., Elvin, J.A., Yan, C., DeMayo, J., DeMayo, F.J., Horton,
.F., Byrne, M.C., and Matzuk, M.M. (2002). Knockout of pentraxin
, a downstream target of growth differentiation factor-9, causes
emale subfertility. Mol. Endocrinol. 16, 1154–1167.
idal Alles, V., Bottazzi, B., Peri, G., Golay, J., Introna, M., and Man-
ovani, A. (1994). Inducible expression of PTX3, a new member of
he pentraxin family, in human mononuclear phagocytes. Blood 84,
483–3493.
